Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens.
The comparative in-vitro activity of CP-99219, a new quinolone, against Haemophilus influenzae (150 isolates), Moraxella catarrhalis (100), Streptococcus pneumoniae (80) and Group A beta-haemolytic streptococci (40) was determined using an agar dilution technique. CP-99219 was the most active compound tested against M. catarrhalis (MIC50 = 0.015 mg/L, MIC90 = 0.03 mg/L). Ceftriaxone, CP-99219 and ciprofloxacin were the three most active agents tested against H.influenzae. CP-99219 showed good activity, 16-fold greater than that of ciprofloxacin, against S.pneumoniae (MIC50 = 0.12 mg/L; MIC90 = 0.25 mg/L) and was also active against Group A streptococci. Clinical studies regarding the use of CP-99219 in respiratory tract infections seem indicated.
Sefton
A M
AM
Department of Medical Microbiology, London Hospital Medical College, UK.
Maskell
J P
JP
Seymour
A C
AC
Minassian
M
M
Williams
J D
JD
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects*; D006801:Humans; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects*; D009287:Naphthyridines / Q000494:pharmacology*; D010406:Penicillins / Q000494:pharmacology; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013297:Streptococcus pyogenes / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D018942:Macrolides; D009287:Naphthyridines; D010406:Penicillins; C080163:trovafloxacin